HR-Positive and Triple-Negative Metastatic Breast Cancer — An Interview with Dr Laura Huppert on Optimal Integration of ADCs into Treatment (Companion Faculty Lecture)
Update: 2025-10-13
Description
Featuring a slide presentation and related discussion from Dr Laura Huppert, including the following topics:
- Overview of approved antibody-drug conjugates (ADCs) for metastatic hormone receptor-positive HER2-negative breast cancer — trastuzumab deruxtecan, sacituzumab govitecan and datopotamab deruxtecan(0:00 )
- Approved and investigational ADCs for metastatic triple-negative breast cancer (17:18 )
- Sequencing of ADCs for metastatic HER2-negative breast cancer; future research directions (26:10 )
Comments
In Channel























